Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib-Reference-Cited by-同舟云学术

Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib

Published:2016-08-12 Issue:6 Volume:118 Page:890-901
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Beuselinck Benoit¹²³,Jean-Baptiste Johnny¹²,Schöffski Patrick³,Couchy Gabrielle¹²,Meiller Clément¹²,Rolland Frederic⁴,Allory Yves⁵,Joniau Steven⁶,Verkarre Virginie⁷,Elaidi Reza⁸,Lerut Evelyne⁹,Roskams Tania⁹,Patard Jean-Jacques¹⁰,Oudard Stephane²⁸,Méjean Arnaud¹¹,Lambrechts Diether¹²¹³,Zucman-Rossi Jessica¹²⁸

Affiliation:

1. Inserm; UMR-1162; Génomique fonctionnelle des tumeurs solides; IUH; Paris France

2. Sorbonne Paris Cité; Faculté de Médecine; Université Paris Descartes; Paris France

3. Department of General Medical Oncology and Laboratory for Experimental Oncology; University Hospitals Leuven; Leuven Cancer Institute; KU Leuven; Leuven Belgium

4. Department of Medical Oncology; Institut de Cancérologie de l'Ouest; Saint Herblain France

5. Department of Pathology; Assistance Publique-Hôpitaux de Paris; Hôpital Henri Mondor; Créteil France

6. Department of Urology; University Hospitals Leuven; Leuven Cancer Institute; KU Leuven; Leuven Belgium

7. Department of Pathology; Assistance Publique-Hôpitaux de Paris; Hôpital Necker-Enfants malades; Paris France

8. Department of Medical Oncology; Assistance Publique-Hôpitaux de Paris; Hôpital Européen Georges Pompidou; Paris France

9. Department of Pathology; University Hospitals Leuven; KU Leuven; Leuven Belgium

10. Department of Urology; Hôpital Bicêtre; Le Kremlin-Bicêtre France

11. Department of Urology; Assistance Publique-Hôpitaux de Paris; Hôpital Européen Georges Pompidou; Paris France

12. Laboratory for Translational Genetics; Department of Oncology; KU Leuven; Leuven Belgium

13. Vesalius Research Center; VIB; Leuven Belgium

Funder

Fondation Martine Midy (Paris, France)

Fonds voor Wetenschappelijk Onderzoek Vlaanderen (Belgium)

Stichting Tegen Kanker

F. Hoffmann-La Roche

Sanofi-Aventis

ARTUR (Association pour la recherche sur les tumeurs du rein, Paris, France)

Fondation ARC pour la Recherche sur le Cancer

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.13585/fullpdf

Reference19 articles.

1. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

2. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2009

3. Resistance to targeted therapy in renal-cell carcinoma;Rini;Lancet Oncol,2009

4. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients;Dornbusch;J Cancer Res Clin Oncol,2016

5. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials;Lambrechts;Lancet Oncol,2012

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Progress on Circulating Tumor DNA in Renal Cell Carcinoma;annals of urologic oncology;2023-06-16

2. Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies;Cancers;2022-12-14

3. The Association of Biochemical and Genetic Biomarkers in VEGF Pathway with Depression;Pharmaceutics;2022-12-09

4. Genetic Polymorphisms in VEGFR Coding Genes (FLT1/KDR) on Ranibizumab Response in High Myopia and Choroidal Neovascularization Patients;Pharmaceutics;2022-07-26

5. Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial;Therapeutic Advances in Medical Oncology;2022-01